CARY STREET PARTNERS FINANCIAL LLC
Position in GILD — Gilead Sciences, Inc.
CIK 1475045
RICHMOND, VA
Position in GILD
as of Jun 30, 2026
· filed Jul 17, 2026
Position Value
$1,563,835
+$719,533 QoQ
Shares Held
12,378
+104.3% QoQ
Ownership
0.001%
of shares outstanding
% of Portfolio
0.07%
of 13F equity value
Holder Rank
#907
of 2,266 holders
Holding Since
Dec 2024
7 quarters on record
Voting authority
Sole 48%
Shared 0%
None 52%
Common Shares in GILD Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026CARY STREET PARTNERS FINANCIAL LLC holds $153,520,894 across 14 Drug Manufacturers - General names. GILD ranks #9 (1.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LLY |
ELI LILLY & Co
|
30,891 | $37,051,594 | |
| 2 | JNJ |
Johnson & Johnson
|
139,478 | $35,423,227 | |
| 3 | ABBV |
AbbVie Inc.
|
132,877 | $33,437,167 | |
| 4 | MRK |
Merck & Co., Inc.
|
201,087 | $25,839,679 | |
| 5 | AMGN |
Amgen Inc
|
17,422 | $6,308,854 | |
| 6 | BMY |
Bristol Myers Squibb Co
|
104,335 | $6,011,782 | |
| 7 | PFE |
Pfizer Inc
|
153,898 | $3,705,863 | |
| 8 | AZN |
Astrazeneca PLC
|
13,070 | $2,478,333 |
All Filings in GILD
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1,563,835 | 12,378 | Shares | Defined | 2026-07-17 | |
| 2026-03-31 | $844,302 | 6,058 | Shares | Defined | 2026-04-29 | |
| 2025-12-31 | $845,310 | 6,887 | Shares | Defined | 2026-02-09 | |
| 2025-09-30 | $612,720 | 5,520 | Shares | Defined | 2025-11-10 | |
| 2025-06-30 | $687,836 | 6,204 | Shares | Defined | 2025-08-13 | |
| 2025-03-31 | $694,037 | 6,194 | Shares | Defined | 2025-05-09 | |
| 2024-12-31 | $586,272 | 6,347 | Shares | Defined | 2025-02-14 | |
| No filing history on record for this holder in this stock. | ||||||